title: Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru.
abstract: The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p=0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.
authors: Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
authors: Mario
authors: M
authors: Ponce
authors: Cesar
authors: C
authors: Ugarte-Gil
authors: Carlos
authors: C
authors: Zamudio
authors: Fiorella
authors: F
authors: Krapp
authors: Eduardo
authors: E
authors: Gotuzzo
authors: Carlos
authors: C
authors: Seas
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D010568:Peru / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D013307:Streptomycin / Q000008:administration & dosage*; D017211:Treatment Failure; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents; D013307:Streptomycin